SNSE NASDAQ

Sensei Biotherapeutics, Inc. (SNSE) is a biopharmaceutical firm dedicated to discovering and advancing immunotherapies, primarily for cancer treatment. The company's innovative approaches include its proprietary ImmunoPhage platform. This immunotherapy leverages bacteriophages to orchestrate a precise and robust innate and adaptive immune response. They also employ the Tumor Microenvironment Activated Biologics (TMAB) platform. This system is engineered to unleash T-cells' anti-tumor capabilities, utilizing human monoclonal antibodies specifically designed to operate within the tumor's immediate environment and target key immune checkpoints or other crucial signaling pathways. Sensei Biotherapeutics' pipeline features SNS-101, a monoclonal antibody developed for cancer therapy, and SNS-401-NG, an ImmunoPhage vaccine engineered to target a range of tumor antigens. Furthermore, they collaborate with The University of Washington on the research and development of a vaccine for Merkel cell carcinoma. Established in 1999, originally as Panacea Pharmaceuticals, Inc., Sensei Biotherapeutics maintains its headquarters in Rockville, Maryland.